Biopharma companies need today to maximize the value of their pipeline, and one of the strategies is to identify new indications or uses for existing drugs. Many safe compounds, initially intended to cure one main disease, can be useful for treating other diseases as well. Examples abound, like the one of Sildenafil (ViagraTM). Drug reprofiling has to be a directed, rational and optimized process, where new indications can be predicted and identified in weeks, not in months or years. For doing so, Anaxomics' Systems Biology approach explores the full potential of the analysis of the biochemical networks in order to identify the new indications for known drugs.
“In our Global Collaborative Initiative, we offer to biopharma companies all over the world a quick and systematic analysis of their pipeline, in a flexible model that may consist on a fee-for-service approach, or a shared-risk approach, depending on the clients' wish”, says Dr Jordi Naval, CEO of Anaxomics. “We have already helped many companies to reprofile drugs for Alzheimer Disease, Seizures, Oncology, Hypertension and Diabetes, among others”, confirms Dr Naval.
Drug Reprofiling is considered as one of the most interesting sources of compounds for treating diseases that still have no cure, like Alzheimer Disease, Multiple Sclerosis, and many others.
Systems Biology is a new technology in drug discovery and medicine that integrates all the information arising from the “Omics” sciences into a complex network that emulates the behaviour of our biochemistry and physiology. This network, similar to a social network, can be trained to predict the safety and efficacy of new medicines.
About Anaxomics
Anaxomics is one of the most innovative companies active in the field of applications of Systems Biology to Medicine and Drug Discovery. Anaxomics works for Biopharma companies all over the world, helping them discover and evaluate safer and more effective medicines. Anaxomics has offices in Barcelona and Lausanne, and employs more than 20 skilled professionals in the field. For more information, please visit www.anaxomics.com. Anaxomics will be presenting at the next BIO-EUROPE 2010 in Munich, Germany.
BARCELONA, NOVEMBER 2ND 2010
Contact Info: VESNA RADOVANOVIC vesna@anaxomics.com Tel +34 93 451 67 17
www.anaxomics.com
